Last reviewed · How we verify
EUFLEXXA
At a glance
| Generic name | EUFLEXXA |
|---|---|
| Also known as | hyaluronic acid injection |
| Sponsor | Georgia Institute for Clinical Research, LLC |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Euflexxa for the Treatment of Osteoarthritis (NA)
- Phase 1b Clinical Trial to Evaluate PEP and EUFLEXXA for Knee Osteoarthritis (KOA) (PHASE1)
- Intra-articular Platelet-Rich Plasma Compared With Viscosupplementation in the Treatment of Knee Osteoarthritis (PHASE2)
- Ultrasound Guided Knee Injections in Musculoskeletal Medicine (NA)
- Comparative Effectiveness of Hyaluronic Acid Injections for Management of Knee Osteoarthritis
- Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OA (NA)
- To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knee After Hyaluronic Acid Injection (PHASE4)
- A Study of Hyaluronate Injectable Viscosupplement for Treatment of Osteoarthritis of the Knee (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EUFLEXXA CI brief — competitive landscape report
- EUFLEXXA updates RSS · CI watch RSS
- Georgia Institute for Clinical Research, LLC portfolio CI